Today, CEO @drsmusunuri announced a major advancement for #OCU410 and #geographicatrophy: the first patient dosed in our global Phase 3 trial.
We are one step closer to a potential one-time treatment for life and our target of 3 BLAs by 2028. ��https://t.co/z2IBcOwzyI $OCGN
What makes #OCU400 different?
OCU400 is designed to address multiple RP mutations through a potential one-time therapy.
Follow us for updates as we advance OCU400 toward a planned BLA submission this year.
#RetinitisPigmentosa#GeneTherapy $OCGN
#OCUGEN Here's the Noble vid from yesterday with @drsmusunuri. Q3 looks to be a busy quarter with OCU410ST interm analysis to see if any changes need to be made to the trial, start of the rolling BLA for OCU400 and the start of the OCU410 "Global trial"💪
https://t.co/XqGcuV3gl5
What is #RetinitisPigmentosa (RP)?
RP is a rare inherited eye disease that can lead to vision loss over time. More than 150 genetic mutations can cause RP. #OCU400 is designed to address over 98% RP-associated gene mutations with a single dose. Share to raise awareness. $OCGN
Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage
programs as we work toward filing three BLAs by 2028.
Learn more: https://t.co/7nSj5EJkPZ
#GeneTherapy#Biotech#FinancialUpdate $OCGN
This is more important than ever. $OCGN
I need you all to get this message out there. For the sake of the company and everyone involved.
Give them the confidence that we are serious investors and serious investors vote.
Vote here, vote on our proxy.
You all matter. 🔊